{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Zhao J"],"pubmed_abstract":["The effectiveness of the tyrosine kinase inhibitor ALK (TKI) for non-small cell lung cancer has been confirmed. However, resistance to ALK-TKIs seems inevitable. Mutations in the ALK kinase domain have been reported as an important mechanism of acquired resistance to ALK therapy. However, patients with <i>de novo</i> ALK kinase domain mutations and ALK rearrangements who were not treated with ALK inhibitors have rarely been reported. Here, we report a case of primary drug resistance to first- and second-generation ALK inhibitors in a NSCLC patient with ALK-rearrangement. The next-generation sequencing test of the pathological biopsy showed that the <i>de novo</i> ALK kinase domain mutation F1174L-cis-S1189C may be the cause of primary drug resistance."],"journal":["Frontiers in pharmacology"],"pagination":["1060460"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9727108"],"repository":["biostudies-literature"],"pubmed_title":["Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C <i>de novo</i> mutation: A case report."],"pmcid":["PMC9727108"],"pubmed_authors":["Liu H","Wang B","Guo Y","Liang Y","Qin Y","Fan R","Li X","Guan Y","Li S","Fan J","Zhang X","Zhao J","Wang Z","Wu X"],"additional_accession":[]},"is_claimable":false,"name":"Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C <i>de novo</i> mutation: A case report.","description":"The effectiveness of the tyrosine kinase inhibitor ALK (TKI) for non-small cell lung cancer has been confirmed. However, resistance to ALK-TKIs seems inevitable. Mutations in the ALK kinase domain have been reported as an important mechanism of acquired resistance to ALK therapy. However, patients with <i>de novo</i> ALK kinase domain mutations and ALK rearrangements who were not treated with ALK inhibitors have rarely been reported. Here, we report a case of primary drug resistance to first- and second-generation ALK inhibitors in a NSCLC patient with ALK-rearrangement. The next-generation sequencing test of the pathological biopsy showed that the <i>de novo</i> ALK kinase domain mutation F1174L-cis-S1189C may be the cause of primary drug resistance.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-04-08T11:31:46.434Z","creation":"2024-11-07T10:22:30.326Z"},"accession":"S-EPMC9727108","cross_references":{"pubmed":["36506539"],"doi":["10.3389/fphar.2022.1060460"]}}